- Home
- SNSE vs HOOK Comparison
SNSE vs HOOK Comparison
Compare SNSE & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNSE
- HOOK
- Stock Information
- Founded
- SNSE 2005
- HOOK 2011
- Country
- SNSE United States
- HOOK United States
- Employees
- SNSE N/A
- HOOK N/A
- Industry
- SNSE Biotechnology: Pharmaceutical Preparations
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- SNSE Health Care
- HOOK Health Care
- Exchange
- SNSE Nasdaq
- HOOK Nasdaq
- Market Cap
- SNSE 10.8M
- HOOK 11.9M
- IPO Year
- SNSE 2021
- HOOK 2019
- Fundamental
- Price
- SNSE $7.76
- HOOK $0.91
- Analyst Decision
- SNSE Strong Buy
- HOOK Hold
- Analyst Count
- SNSE 4
- HOOK 3
- Target Price
- SNSE $72.50
- HOOK $4.50
- AVG Volume (30 Days)
- SNSE 25.9K
- HOOK 155.9K
- Earning Date
- SNSE 08-05-2025
- HOOK 08-11-2025
- Dividend Yield
- SNSE N/A
- HOOK N/A
- EPS Growth
- SNSE N/A
- HOOK N/A
- EPS
- SNSE N/A
- HOOK N/A
- Revenue
- SNSE N/A
- HOOK $9,351,000.00
- Revenue This Year
- SNSE N/A
- HOOK N/A
- Revenue Next Year
- SNSE N/A
- HOOK N/A
- P/E Ratio
- SNSE N/A
- HOOK N/A
- Revenue Growth
- SNSE N/A
- HOOK N/A
- 52 Week Low
- SNSE $5.00
- HOOK $0.72
- 52 Week High
- SNSE $17.40
- HOOK $5.66
- Technical
- Relative Strength Index (RSI)
- SNSE 52.43
- HOOK 28.06
- Support Level
- SNSE $6.33
- HOOK $0.86
- Resistance Level
- SNSE $10.99
- HOOK $0.95
- Average True Range (ATR)
- SNSE 1.00
- HOOK 0.06
- MACD
- SNSE 0.12
- HOOK 0.00
- Stochastic Oscillator
- SNSE 41.04
- HOOK 19.90
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.